Similar articles

Abstract: Malignant gliomas are the most devastating tumors in clinical practice and have poorest survival. Immunological treatment of such patients may likely increase the survival and quality of life. dendritic cells (DCs), most potent antigen presenting cells in combination with oral chemotherapeutic agents may be tried for patients giving consent to such treatment. We have successfully combined the two therapies in an adult male patient who was on downhill course after being operated on once with post operation chemotherapy and radiotherapy for glioma in the left parietal area. He received five dendritic cell therapy vaccines in combination with oral chemotherapy and responded dramatically having near normal quality of life for an additional five months with this regime, increasing the survival after operation to 11 months. This therapy is continuing with radiological betterment of the lesion. The DCs are matured with antigen extracted from wax embedded tissue at 6th day of culture. We feel that the treatment can be given to more number of patients to establish its efficacy for the dreaded cancer glioblastoma multiforme.

[1] Chan, P.K.S., Chan, D.P.C., To, K.F., Yu, M.Y., Cheung, J.L.K., Cheng, A.F., 2001. Evaluation of extraction methods from paraffin wax embedded tissues for PCR amplification of human and viral DNA. J. Clin. Pathol., 54(5):401-403.

[2] Davis, F.G., McCarthy, B., Jukich, P., 1999. The descriptive epidemiology of brain tumors. Neuroimaging Clinics of North America, 9:581-594.

[3] Hart, D.N., 2005. Dendritic cell biology evolves into clinical application. The Lancet., 365(9454):102-104.

[4] Liau, L.M., Black, K.L., Martin, N., 2000. Treatment of a glioblastoma patient by vaccination with autologous dendritic cells pulsed with allogenic major histocompatibilty complex class I matched tumor peptides: case report. Neurosurgery Focus, 9:1-5.

[5] Lim, M.N., Leong, C.F., Cheong, S.K., Seow, H.F., 2003. Generation of dendritic cells from acute myeloid leukemia cells and monocytes, our experience. Malays J. Pathol., 25(2):107-112.

[6] Liu, Y., Ng, K.Y., Lillehi, K.O., 2003. Cell-mediated Immunotherapy: a new approach to the treatment of malignant glioma. Cancer Control, 10:138-147.

[7] Lo, Y.M., Mehal, W.Z., Fleming, K.A., 1989. In-vitro amplification of hepatitis B virus sequences from liver tumor DNA and from paraffin wax-embedded tissues using the polymerase the polymerase chain reaction. J. Clin. Pathol., 42:840-846.

[8] Onji, M., Akbar, S.M.F., 2005. On dendritic cell-based therapy for cancers. J. Zhejiang Univ. SCI., 6B(1):1-3.

[9] Sagar, S.M., Israel, M.A., 2001. Primary and Metastatic Tumors of the Nervous System. In: Harrison’s Principles of Internal Medicine, 15 Internationa Ed. McGraw Hill, New Delhi, p.2444.

[10] Steinman, R.M., Dhodhapkar, M., 2001. Active immunization against cancer with dendritic cells: the near future. Int. J. Cancer, 94(4):459-473.

[11] Wheeler, C.J., Das, A., Liu, G., John, S., Black, U., Black, L.K., 2004. Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clinical Cancer Research, 10(16):5316-5326.

[12] Yu, J.S., Liu, G., Ying, H., Yong, W.H., Black, K.L., Wheeler, J.C., 2004. Vaccination with tumor lysate-pulsed Dendritic cells elicit antigen specific cytotoxic T-cells in patients with malignant glioma. Cancer Research, 64(14):4973-4979.